Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis

You'll hear about Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis.

Daliresp (roflumilast) is the first in a new class of oral phosphodiesterase 4 inhibitors. It works by reducing lung inflammation.

It's added to the usual bronchodilator therapy to decrease exacerbations...but only for severe, chronic COPD.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote